CompletedPhase 4ACTRN12610000835044

Influence on hemodynamics of conversion from Calcineurin Inhibitor to Sirolimus in Renal and Liver Transplant patients

Influence on hemodynamics of conversion from Calcineurin Inhibitor to Sirolimus in Renal and Liver Transplant patients older than 18 year

Sponsor

University Hospital Bern

Enrollment

40 participants

Start Date

Sep 1, 2004

Study Type

Interventional

Conditions

renal allograft recipients or liver allograft recipients

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study examines how switching from one type of anti-rejection medication to another (sirolimus) affects blood pressure and blood vessel health in kidney or liver transplant patients. It is for adults aged 18 and older who have received a kidney or liver transplant and have adequate kidney function.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Switch calcineurin inhibitor (CNI) to Sirolimus treatment; Sirolimus dose:Loading dose 10-15 mg/d (at clinicians discretion); d 2-6:3-5 mg/d (at clinicians discretion), after d 7,sirolimus dosage was

Switch calcineurin inhibitor (CNI) to Sirolimus treatment; Sirolimus dose:Loading dose 10-15 mg/d (at clinicians discretion); d 2-6:3-5 mg/d (at clinicians discretion), after d 7,sirolimus dosage was adjusted to target through level of 6–16 ng/mL study duration: 1 year. administration: oral capsule

Locations(1)

Switzerland

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000835044